Cargando…

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

The current influenza vaccine has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here, we design a vaccine utilizing the hypervariable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanekiyo, Masaru, Joyce, M. Gordon, Gillespie, Rebecca A., Gallagher, John R., Andrews, Sarah F., Yassine, Hadi M., Wheatley, Adam K., Fisher, Brian E., Ambrozak, David R., Creanga, Adrian, Leung, Kwanyee, Yang, Eun Sung, Boyoglu-Barnum, Seyhan, Georgiev, Ivelin S., Tsybovsky, Yaroslav, Prabhakaran, Madhu S., Andersen, Hanne, Kong, Wing-Pui, Baxa, Ulrich, Zephir, Kathryn L., Ledgerwood, Julie E., Koup, Richard A., Kwong, Peter D., Harris, Audray K., McDermott, Adrian B., Mascola, John R., Graham, Barney S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380945/ https://www.ncbi.nlm.nih.gov/pubmed/30742080 http://dx.doi.org/10.1038/s41590-018-0305-x

Ejemplares similares

Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2020)

Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes
por: McCraw, Dustin M., et al.
Publicado: (2023)

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages
por: Corbett, Kizzmekia S., et al.
Publicado: (2019)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies
por: Creanga, Adrian, et al.
Publicado: (2021)

Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2019)

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups
por: Hutchinson, Geoffrey, et al.
Publicado: (2022)

Characterization of Influenza Vaccine Hemagglutinin Complexes by Cryo-Electron Microscopy and Image Analyses Reveals Structural Polymorphisms
por: McCraw, Dustin M., et al.
Publicado: (2016)

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera
por: Hutchinson, Geoffrey B., et al.
Publicado: (2023)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
por: Kanekiyo, Masaru, et al.
Publicado: (2015)

Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy
por: Gallagher, John R., et al.
Publicado: (2018)

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
por: Zhou, Tongqing, et al.
Publicado: (2022)

Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection
por: de Bree, Godelieve J., et al.
Publicado: (2017)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses
por: Chuang, Gwo-Yu, et al.
Publicado: (2021)

Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery
por: Liu, Cuiping, et al.
Publicado: (2023)

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine
por: Joyce, M. Gordon, et al.
Publicado: (2016)

Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein
por: Byrne, Patrick O., et al.
Publicado: (2023)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera
por: Yassine, Hadi M., et al.
Publicado: (2018)

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
por: Boyington, Jeffrey C., et al.
Publicado: (2016)

Breathing and tilting: mesoscale simulations illuminate influenza glycoprotein vulnerabilities
por: Casalino, Lorenzo, et al.
Publicado: (2022)

Breathing and Tilting: Mesoscale Simulations Illuminate Influenza Glycoprotein Vulnerabilities
por: Casalino, Lorenzo, et al.
Publicado: (2022)

Mesoscale simulations illuminate the functional interplay and the vulnerabilities of influenza virus glycoproteins
por: Casalino, Lorenzo, et al.
Publicado: (2023)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation
por: Villar, Rina F., et al.
Publicado: (2016)

Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings
por: Boswell, Kristin L., et al.
Publicado: (2022)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

Convergent Evolution in Breadth of Two V(H)6-1-Encoded Influenza Antibody Clonotypes from a Single Donor
por: Wu, Nicholas C., et al.
Publicado: (2020)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4(+) T cells
por: Loré, Karin, et al.
Publicado: (2005)

Activation and lysis of human CD4 cells latently infected with HIV-1
por: Pegu, Amarendra, et al.
Publicado: (2015)

S03-05 OA. A less differentiated memory phenotype of Gag-specific CD4+ T-cells during primary HIV infection associates with viral control at 12 months
por: Maenetje, PW, et al.
Publicado: (2009)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Characterization of Hemagglutinin Negative Botulinum Progenitor Toxins
por: Kalb, Suzanne R., et al.
Publicado: (2017)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_non5k45ktc1fjeqpno65kpka0t